Browse studies

Find your next paid study

12 recruiting studies matching your filters

A Single Arm, Prospective, Multi-Center, Feasibility Study to Evaluate the Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder (NMOSD) Who Have an Impaired Gait

The purpose of this proof of concept study is to assess the acceptability and safety of MR-C-014 in persons with Neuromyelitis optica spectrum disorder (NMOSD)…

Neuromyelitis Optica Spectrum Disorder

Estimated

~$10 – $1,050

Actual pay is set by the research site.

MedRhythms, Inc.NCT06374264

Investigating the Longitudinal Relationships Between Visual Pathway Injury, Radiological and Blood Biomarkers in Multiple Sclerosis and Related Disorders

This study is being conducted to investigate risk factors for disability progression in Multiple Sclerosis and related disorders (MSRD). The primary goal is to…

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Primary Progressive+8 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Cedars-Sinai Medical CenterNCT05204459

A Long-Term, Prospective, Observational, Registry of Patients With Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated With Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT)

Long-term, multicenter, multinational, observational, registry of patients with AQP4+ NMOSD that is designed to collect data on clinical outcomes and safety in…

Neuromyelitis Optica Spectrum DisorderNMOSDAQP4+ NMOSD

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Alexion Pharmaceuticals, Inc.NCT05966467

Longitudinal Investigation of Cortical Demyelination and Meningeal Inflammation in Multiple Sclerosis and Related Disorders

In this protocol, a combination of MRI, blood, and cerebrospinal fluid (CSF) analysis will be used to understand the natural history, underlying immunologic me…

Multiple SclerosisNeuromyelitis OpticaDemyelinating Autoimmune Diseases, CNS

Estimated

~$10 – $750

Actual pay is set by the research site.

Icahn School of Medicine at Mount SinaiNCT05982925

An Observational Pregnancy Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® (Inebilizumab-cdon) During Pregnancy

This is an observational study to monitor female participants exposed to UPLIZNA during pregnancy. This study requires voluntary reporting of pregnancies in fe…

Neuromyelitis Optica Spectrum DisorderPregnancy Related

Estimated

~$10 – $1,125

Actual pay is set by the research site.

AmgenNCT05909761

Observational

Performance and Safety of a Digital Tool for Unsupervised Self-assessment of Neuromyelitis Optica Spectrum Disorder

NMOSDCopilot is a digital tool developed for the self-assessment of Neuromyelitis Optica Spectrum Disorder symptoms that impact patients' functioning and quali…

Neuromyelitis Optica

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Ad scientiamNCT05566769

Clinical and Radiological Outcomes in People With Aquaporin-4 IgG Positive Neuromyelitis Optica Spectrum Disorder Treated With Ravulizumab

This is an observational study to: * evaluate the on-treatment clinical performance of ravulizumab in relation to the pre-treatment time period (time period p…

Neuromyelitis Optica

Estimated

~$10 – $750

Actual pay is set by the research site.

University of Texas Southwestern Medical CenterNCT06398158

Observational Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants expose…

Ultomiris-exposed Pregnant/ PostpartumPregnancyParoxysmal Nocturnal Hemoglobinuria (PNH)+3 more

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Alexion Pharmaceuticals, Inc.NCT06312644

Phase 3

A Phase III, Multicenter, Open-Label, Uncontrolled Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

This study will primarily evaluate the pharmacokinetics of satralizumab in pediatric patients aged 2-11 years with anti-aquaporin-4 (AQP4) antibody seropositiv…

Neuromyelitis Optica Spectrum DisorderNMOSD

Estimated

~$50 – $2,250

Actual pay is set by the research site.

Hoffmann-La RocheNCT05199688

Observational

Impact of a Structured Wellness Behavioral Intervention on Quality of Life in NMOSD

This project aims to study whether a structured wellness program intervention can improve quality of life among people living with Neuromyelitis Optica Spectru…

Neuromyelitis Optica Spectrum Disorder (NMOSD)

Estimated

~$10 – $750

Actual pay is set by the research site.

Icahn School of Medicine at Mount SinaiNCT06780709

CorEvitas SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD)

This is a Prospective, observational research study for patients with NMOSD under the care of a licensed neurologist. Approximately 800 patients and 35 clinica…

Neuromyelitis Optica Spectrum Disorder

Estimated

~$10 – $1,125

Actual pay is set by the research site.

CorEvitasNCT04886492

Phase 2

An Open-Label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

A Phase 2, open-label, multicenter study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of inebilizumab in eligible pediatric partici…

Neuromyelitis Optica Spectrum Disorder

Estimated

~$75 – $3,000

Actual pay is set by the research site.

AmgenNCT05549258